Nivolumab Elicits Statistically Significant Improvement in RFS in Stage IIB/C Melanoma
Source: Onc Live, September 2022
Adjuvant nivolumab (Opdivo) monotherapy elicited a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) compared with placebo for patients with completely resected stage IIB/C melanoma, according to a press release from Bristol Myers Squibb (BMS).
The findings met the primary end point of the phase 3 CheckMate 76K trial (NCT04099251). Moreover, at the time of the prespecified interim analysis, investigators identified no new safety signals with the PD-1 inhibitor. BMS will complete a full assessment of the trial and plans to share the findings at an upcoming medical meeting.
“Patients with stage IIB/C melanoma are at high risk of disease recurrence, with approximately one-third of stage IIB and half of stage IIC patients experiencing recurrence within 5 years after surgery,” Gina Fusaro, PhD, development program lead of melanoma at BMS said in a press release. “The results of the CheckMate 76K study represent a significant advancement for patients with stage IIB/C melanoma and an extension of our legacy in the treatment of melanoma.”